Perspective
Bevacizumab with first-line chemotherapy for Medicare patients with metastatic colorectal cancer: Do the risks outweigh the benefits?
Abstract
No single randomized controlled trial (RCT) can address
every possible clinical scenario in the practice of oncology.
Registry studies are a valuable tool to further describe the
effectiveness of an intervention when discrepancies exist
between a clinical trial population and the “real world”
patient population, or when additional trials are not feasible.
In a recent publication, Meyerhardt et al. (1) analyzed the
Surveillance, Epidemiology, and End Results (SEER)-
Medicare database to determine the overall survival (OS)
benefit of adding bevacizumab to combination chemotherapy
for Medicare patients with metastatic colorectal cancer
(CRC).
every possible clinical scenario in the practice of oncology.
Registry studies are a valuable tool to further describe the
effectiveness of an intervention when discrepancies exist
between a clinical trial population and the “real world”
patient population, or when additional trials are not feasible.
In a recent publication, Meyerhardt et al. (1) analyzed the
Surveillance, Epidemiology, and End Results (SEER)-
Medicare database to determine the overall survival (OS)
benefit of adding bevacizumab to combination chemotherapy
for Medicare patients with metastatic colorectal cancer
(CRC).
